down arrow

Palatin Technologies, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6960775020
USD
15.72
15.33 (3913.28%)

Feb 06

ASE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

15.4516.14

52 Week

0.0958.00
Valuation
Technical
Day's Volume

CASH

9.48 k

Shareholding (Sep 2025)

FII

0.20%

Held by 11 FIIs

DII

97.97%

Held by 2 DIIs

Promoter

0.00%

How big is Palatin Technologies, Inc.?

22-Jun-2025

As of June 18, Palatin Technologies, Inc. has a market capitalization of 5.25 million, categorizing it as a Micro Cap company, with net sales of 0.35 million and a net profit of -23.32 million for the latest four quarters. As of June 2024, shareholder's funds were -0.11 million, and total assets were 10.74 million.

Market Cap: As of Jun 18, Palatin Technologies, Inc. has a market capitalization of 5.25 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.35 million and a net profit of -23.32 million.<BR><BR>Balance Sheet Snapshot: As of June 2024, the company's shareholder's funds stood at -0.11 million, while total assets were reported at 10.74 million.

View full answer

What does Palatin Technologies, Inc. do?

22-Jun-2025

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted therapeutics that affect the melanocortin and natriuretic peptide receptor systems. It operates as a micro-cap company with a market cap of $5.25 million and reported a net profit loss of $5 million as of March 2025.

Overview:<BR>Palatin Technologies, Inc. is a biopharmaceutical company engaged in developing targeted therapeutics that modulate the melanocortin and natriuretic peptide receptor systems, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 5.25 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.36<BR>Return on Equity: 365.24%<BR>Price to Book: -0.82<BR><BR>Contact Details:<BR>Address: 4B Cedarbrook Dr, CRANBURY NJ: 08512-3641<BR>Tel: 1 609 4952200<BR>Website: https://www.palatin.com/

View full answer

Who are in the management team of Palatin Technologies, Inc.?

22-Jun-2025

As of March 2022, the management team of Palatin Technologies, Inc. includes Dr. John Prendergast (Independent Chairman), Dr. Carl Spana (President and CEO), and several Independent Directors: Mr. Robert deVeer, Dr. Alan Dunton, Mr. Joseph Hull, Dr. Anthony Manning, and Ms. Arlene Morris. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Palatin Technologies, Inc. includes the following individuals:<BR><BR>- Dr. John Prendergast, who serves as the Independent Chairman of the Board.<BR>- Dr. Carl Spana, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Robert deVeer, who is an Independent Director.<BR>- Dr. Alan Dunton, who is also an Independent Director.<BR>- Mr. Joseph Hull, another Independent Director.<BR>- Dr. Anthony Manning, who serves as an Independent Director.<BR>- Ms. Arlene Morris, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

View full answer

Is Palatin Technologies, Inc. overvalued or undervalued?

20-Sep-2025

As of February 13, 2025, Palatin Technologies, Inc. has deteriorated to a "does not qualify" valuation grade due to negative financial ratios and a year-to-date return of -84.68%, indicating it is overvalued and not a viable investment compared to its peers and the S&P 500.

As of 13 February 2025, the valuation grade for Palatin Technologies, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its negative valuation ratios, including a Price to Book Value of -0.73, an EV to EBIT of -0.09, and an EV to EBITDA of -0.09, which suggest that the company is struggling financially compared to its peers. <BR><BR>In comparison, KALA BIO, Inc. has a P/E ratio of -2.7752 and Entera Bio Ltd. shows a P/E of -8.6141, both reflecting similarly poor financial health. Palatin's stock has underperformed significantly against the S&P 500, with a year-to-date return of -84.68% compared to the S&P 500's 12.22%, reinforcing the notion that the stock is not a viable investment at its current valuation.

View full answer

Is Palatin Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Palatin Technologies, Inc. shows a mildly bullish technical trend, with mixed indicators and significant underperformance of -84.68% year-to-date compared to the S&P 500's 12.22%.

As of 2 September 2025, the technical trend for Palatin Technologies, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD also reflects a mildly bullish stance. However, the daily moving averages indicate a bearish trend. The Bollinger Bands show a mildly bullish signal on the weekly chart but are bearish on the monthly chart. The KST is bullish on the weekly timeframe but bearish monthly, and the Dow Theory indicates a mildly bearish stance weekly with no trend monthly. <BR><BR>In terms of performance, Palatin has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -84.68% versus the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed indicators and substantial underperformance relative to the benchmark.

View full answer

Compare Palatin Technologies, Inc. with Similar Stocks

Entera Bio Ltd.Acasti Pharma, Inc.Alzamend Neuro, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 28 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

-480.62%

stock-summary
Price to Book

27.77

Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Sep 2025)
Net Profit:
5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2583.97%
0%
2583.97%
6 Months
3472.73%
0%
3472.73%
1 Year
1781.06%
0%
1781.06%
2 Years
1604.25%
0%
1604.25%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Palatin Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-64.30%
EBIT Growth (5y)
-194.02%
EBIT to Interest (avg)
-17.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.36
Sales to Capital Employed (avg)
2.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.56%
ROCE (avg)
0
ROE (avg)
8.56%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.73
EV to EBIT
-0.09
EV to EBITDA
-0.09
EV to Capital Employed
-0.27
EV to Sales
2.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (1.83%)

Foreign Institutions

Held by 11 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 160.26% vs -32.20% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.70",
          "val2": "-7.60",
          "chgp": "161.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.70",
          "val2": "-7.80",
          "chgp": "160.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "526.80%",
          "val2": "0.00%",
          "chgp": "52.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is -100.00% vs -8.16% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 41.75% vs -23.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "4.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.40",
          "val2": "-29.60",
          "chgp": "24.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-7.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.30",
          "val2": "-29.70",
          "chgp": "41.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-6,743.30%",
          "chgp": "674.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
8.80
0.00
Operating Profit (PBDIT) excl Other Income
4.70
-7.60
161.84%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.70
-7.80
160.26%
Operating Profit Margin (Excl OI)
526.80%
0.00%
52.68%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 160.26% vs -32.20% in Sep 2024

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Jun'25stock-summary

Jun'25
Jun'24
Change(%)
Net Sales
0.00
4.50
-100.00%
Operating Profit (PBDIT) excl Other Income
-22.40
-29.60
24.32%
Interest
0.00
0.00
Exceptional Items
0.00
-7.70
100.00%
Consolidate Net Profit
-17.30
-29.70
41.75%
Operating Profit Margin (Excl OI)
0.00%
-6,743.30%
674.33%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is -100.00% vs -8.16% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 41.75% vs -23.75% in Jun 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Palatin Technologies, Inc. stock-summary
stock-summary
Palatin Technologies, Inc.
Pharmaceuticals & Biotechnology
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.
Company Coordinates stock-summary
Company Details
4B Cedarbrook Dr , CRANBURY NJ : 08512-3641
stock-summary
Tel: 1 609 4952200
stock-summary
https://www.palatin.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."